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Management of fibromyalgia syndrome – an
interdisciplinary evidence-based guideline
Behandlung des Fibromyalgiesyndroms – eine interdisziplinäre
S3-Leitlinie
Abstract
The prevalence of fibromyalgia syndrome (FMS) of 1–2% in the general
populationassociatedwithhighdisease-relatedcostsandtheconflicting
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Bernhard Arnold
2
dataontreatmenteffectivenesshadledtothedevelopmentofevidence-
Wolfgang Eich
3
basedguidelinesdesignedtoprovidepatientsandphysiciansguidance
Eva Felde
4 in selecting among the alternatives. Until now no evidence-based inter-
disciplinary (including patients) guideline for the management of FMS
was available in Europe. Christl Flügge
5
Peter Henningsen
6
Therefore a guideline for the management of fibromyalgia syndrome
(FMS) was developed by 13 German medical and psychological associ- Markus Herrmann
7
ationsandtwopatientself-helporganisations.Thetaskwascoordinated Volker Köllner
8
by two German scientific umbrella organisations, the Association of the
Edeltraud Kühn
9
Scientific Medical Societies in Germany AWMF and the German Inter-
Detlev Nutzinger
10 disciplinary Association of Pain Therapy DIVS. A systematic search of
the literature including all controlled studies, systematic reviews and Martin Offenbächer
11
meta-analysesofpharmacologicalandnon-pharmacologicaltreatments
Marcus Schiltenwolf
12
of FMS was performed in the Cochrane Library (1993–12/2006),
Claudia Sommer
13 Medline (1980–12/2006), PsychInfo (1966–12/2006) and Scopus
(1980–12/ 2006). Levels of evidence were assigned according to the Kati Thieme
14
classificationsystemoftheOxford-CentreforEvidenceBasedMedicine.
Ina Kopp
15
Grading of the strengths of recommendations was done according to
theGermanprogramfordiseasemanagementguidelines.Standardized
procedures were used to reach a consensus on recommendations. The 1 Department of Internal
Medicine I, Klinikum guideline was reviewed and finally approved by the boards of the soci-
eties involved and published online by the AWMF on april 25, 2008: Saarbrücken, Germany;
German Interdisciplinary http://www.uni-duesseldorf.de/AWMF/ll/041-004.htm.Ashortversion
Association of Pain Therapy
DIVS
of the guideline for patients is available as well: http://www.uni-
duesseldorf.de/AWMF/ll/041-004p.htm.
The following procedures in the management of FMS were strongly re-
commended: information on diagnosis and therapeutic options and
2 Pain clinic, Klinikum
Dachau, Germany; German
Association for the Study of
Pain DGSS
patient-centeredcommunication,aerobicexercise,cognitiveandoperant
behaviouraltherapy,multicomponenttreatmentandamitriptyline.Based
on expert opinion, a stepwise FMS-management was proposed. Step 1 3 Department Internal
Medicine II, University comprisesconfirmingthediagnosisandpatienteducationandtreatment
of physical or mental comorbidities or aerobic exercise or cognitive be- Clinics of Heidelberg,
Germany; German Society
of Rheumatology DGRh
havioural therapy or amitriptyline. Step 2 includes multicomponent
treatment. Step 3 comprises no further treatment or self-management
(aerobicexercise,stressmanagement)and/orboostermulticomponent 4 German Fibromyalgia
Association, Seckach,
Germany
therapy and/or pharmacological therapy (duloxetine or fluoxetine or
paroxetineorpregabalinortramadol/aminoacetophen)and/orpsycho-
therapy (hypnotherapy or written emotional disclosure) and/or physical 5 Central Association of
Physiotherapy ZVK, Köln,
Germany
therapy(balneotherapyorwholebodyheattherapy)and/orcomplement-
arytherapies(homoeopathyorvegetariandiet).Thechoiceoftreatment
options should be based on informed decision-making and respect of
the patients’ preferences.
6 Department of
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management
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German College of Zusammenfassung
Die Prävalenz des Fibromyalgiesyndroms (FMS) in der allgemeinen Be-
völkerung beträgt 1–2%. Aufgrund der mit FMS verbundenen hohen
Psychosomatic Medicine
DKPM
Krankheitskosten und den widersprüchlichen Daten zur Wirksamkeit 7 Institute of General
Medicine, Otto-von- einzelnerBehandlungsformenwurdenevidenzbasierteLeitlinienentwi-
Guericke-Universität ckelt, um Ärzten und Patienten einen Entscheidungshilfe zu geben.
Magdeburg, Germany; Bisher war in Europa keine interdisziplinäre evidenzbasierte Leitlinie
unter Einschluss von Patienten zum FMS verfügbar.
German Society of General
and Family Medicine
DEGAM Deswegenwurdevon13deutschenmedizinischenundpsychologischen
Fachgesellschaften und zwei Patientenselbsthilfeorganisationen eine
8 Department of
Psychosomatic Medicine,
Leitlinie zu Therapie des FMS entwickelt. Die Durchführung wurde von
derDeutschenInterdisziplinärenVereinigungfürSchmerztherapieDIVS
Bliestal Clinics, Blieskastel,
und der Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Germany; German Society
Fachgesellschaften in Deutschland AWMF koordiniert. Eine systemati- of Psychosomatic Medicine
scheLiteratursucheallerkontrollierteStudien,systematischerReviews andMedicalPsychotherapy
DGPM und Metaanalysen wurde über die Datenbanken Cochrane Library
(1993–12/2006), Medline (1980–12/2006), PsychInfo 9 German League of People
with Arthritis and (1966–12/2006)undScopus(1980–12/2006)durchgeführt.Fürdie
Vergabe von Evidenzklassen wurde das System des Oxford-Centre for Rheumatism, Bonn,
Germany EvidenceBasedMedicineverwendet.FürdieVergabevonEmpfehlungs-
gradenwurdedieEmpfehlungsgraduierungdernationalenVersorgungs-
10 Medical-psychosomatic
clinic, Bad Bramstedt, leitlinienverwendet.DieErstellungderEmpfehlungenerfolgteineinem
mehrstufigennominalenGruppenprozess,welchervoneinerVertreterin Germany; German Society
der AWMF moderiert wurde. Die Leitlinie wurde von den Vorständen ofPsychiatry,Psychotherapy
and Neurology DGPPN der beteiligten Fachgesellschaften begutachtet und genehmigt. Die
wissenschaftliche Lang- und Kurzversion der Leitlinie wurde am 25.
11 Generation Research
Program, Ludwig- April 2008 von der AWMF ins Internet gestellt: http://www.uni-
duesseldorf.de/AWMF/ll/041-004.htm.EineKurzversionfürPatienten Maximilian-University
ist ebenfalls verfügbar: http://www.uni-duesseldorf.de/AWMF/ll/041-
004p.htm.
München, Bad Tölz,
Germany;DeutscheSociety
FolgendeTherapieverfahrenerhielteneinestarkeEmpfehlung:Informa-
tionen über Diagnose und Behandlungsmöglichkeiten, patienten-zen-
of Physical Medicine and
Rehabilitation DGPMR
trierte Kommunikation, aerobes Ausdauertraining, kognitive und ope- 12 Section Pain Therapy,
University Clinic of ranteVerhaltenstherapie,multimodaleTherapieundAmitriptylin.Basie-
rend auf Expertenmeinung wurde eine stufenweise Behandlung des Orthopedics, Heidelberg,
FMSempfohlen:Stufe1beinhaltetDiagnosebestätigungundPatienten- Germany; German Society
of Orthopedics and
Orthopedic Surgery DGOOC
schulungund/oderBehandlungkörperlicherundpsychischerKomorbi-
ditäten oder aerobes Ausdauertraining oder kognitive und operante
Verhaltenstherapie oder Amitriptylin. Stufe 2 beinhaltet multimodale 13 Department of Neurology,
University Würzburg, Therapie. Stufe 3 umfasst die folgenden Behandlungsoptionen: keine
Germany; German Society
of Neurology DGN
weitereBehandlungoderSelbstmanagement(aerobesAusdauertraining,
Stressmanagement) und/oder multimodale Auffrischungstherapie
und/oder phamakologische Therapie (Duloxetin oder Fluoxetin oder 14 Central Institute of Mental
Health, Mannheim, PregabalinoderTramadol/Paracetamol)und/oderpsychotherapeutische
Verfahren (Hypnotherapie oder therapeutisches Schreiben) oder physi- Germany; German Society
of Psychological Pain kalische Therapie (Balneotherapie oder Ganzkörperwärmetherapie)
Research and Therapy
DGPSF
und/oder komplementäre Therapien (Homöopathie oder vegetarische
Kost).DieWahlderBehandlungsoptionensollaufgemeinsameEntschei-
dungsfindung und unter Berücksichtigung der Patientenpräferenzen
durchgeführt werden.
15 Institute of Theoretical
Surgery,UniversityMarburg,
Germany;Associationofthe
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According to the criteria of the American College of
Rheumatology (ACR), fibromyalgia syndrome (FMS) is
defined as chronic widespread pain and tenderness in
atleastelevenof18definedtenderpoints[1].Population
based estimates of the prevalence of FMS range from
0.5% to 5.8% [2]. FMS is frequently associated with fa-
tigue,sleepdisorder,otherfunctionalsomaticsyndromes,
mentalandphysicaldisorders[3],[4],aswellasdisability
anddiminishedqualityoflife[5].FMSpatientsincurhigh
direct medical costs [6], [7] and consume significant in-
direct costs (e.g., sick-leave, disability pension) [5], [8].
Effectivetreatmentoptionsarethereforeneededforboth
medical and economic reasons [9].
Despite increased knowledge about FMS, there is cur-
rently no cure. The absence of any definitive treatment
has resulted in a variety of pharmacological and non-
pharmacological treatments being prescribed and used
by patients diagnosed with FMS [10], [11]. The results
ofvarioustreatmentshavebeenmodestandinconsistent.
The large number of patients diagnosed with FMS and
the conflicting data on treatment effectiveness has led
to the development of a number of attempts to create
evidence-based guidelines designed to provide patients
and physicians guidance in selecting among the alterna-
tives.
Until now three evidence-based guidelines on the man-
agement of FMS were available. The interdisciplinary
guideline of the American Pain Society was developed by
13 experts in various pain management disciplines and
based on a systematic search of the literature until April
2004 [12]. The recommendations of the European
League Against Rheumatism (EULAR) were given by 19
experts, mainly rheumatologists, of 11 European coun-
tries, and based on a search of the literature until
December 2005 [13]. Most non-pharmacological ther-
apies were not considered by EULAR. The two guideline-
groupsdidnotincludeFMS-patientorganizationsanddid
not report how consensus on the recommendations was
achieved. Therefore we decided to develop an evidence-
based guideline which
• expandedthesearchofliteratureuntilDecember2006
including all non-pharmacological therapies,
• included members of patient organizations into the
guideline group having equal rights,
• was based on a consensus of medical and psycholo-
gical scientific societies
• followed defined procedures to reach a consensus on
recommendations.
The elaborate German version of the guideline is online
available(http://www.uni-duesseldorf.de/AWMF/ll/041-
004.htm). Below a summary of the methodology and the
recommendationsontherapyisgiventodisseminatethe
guideline into the German and non-German speaking
scientific community.
Methods
Selection of the guideline group
The development of the guideline was initiated and co-
ordinated by the German Interdisciplinary Association of
Pain Therapy (DIVS), an umbrella organisation of 19 sci-
entificsocietiesengagedinpaintherapy.TheAssociation
of the Scientific Medical Societies of Germany (AWMF),
the umbrella organisation of 152 scientific medical soci-
etiesinGermanyandtheGermanSocietyofGastroenter-
ology DGVS gave methodological support. The steering
committee of AWMF consisted of 15 experts from 10
differentscientificsocietiesandtwopatientsrepresenting
the two largest German FMS self-help organisations. All
healthprofessionalsengagedinthemanagementofFMS
were represented within the steering committee and in
the eight work groups. The two chairs of the steering
committee had been deputized by two German umbrella
organizations, the DIVS (W. Häuser) and the AWMF
(I. Kopp). The chair of the DIVS was responsible for the
coordination of the search and the analysis of literature.
ThechairoftheAWMFwasresponsiblefortheconsensus
procedures to establish the recommendations. Both
chairs were not permitted to vote on the recommenda-
tions. Two members from different medical and psycho-
logical societies were included in each work group. All
membersofthesteeringcommitteeandtheworkgroups
had been nominated by the board of directors of the sci-
entific societies engaged in the guideline. Members of
thesteeringcommitteewereselectedbecauseofscientif-
icandclinicalFMSexpertises,membersoftheworkgroup
wereselectedbecauseofscientificand/orclinicalexpert-
ise. Furthermore, gender, hierarchical position within the
medicalsystem,andexperiencewereequallydistributed
attributes amongst members of the work groups. Thus
the whole guideline group comprised 58 persons.
Financing of the guideline
The guideline was financed by membership fees of the
scientific societies and two self-help organisations. One
grant was given by a private founder to one self-help or-
ganisation. No other support was accepted.
Data sources and study selection
We searched the Cochrane Library (1993–12/2006),
Medline (1980–12/2006), PsychInfo (1966–12/2006)
andScopus(1980–12/2006).Meta-analyses,systematic
reviews and controlled trials were reviewed. References
were consistently checked for any relevant articles. If
none of these data sources was available for therapies
frequently used in Germany, uncontrolled trials were re-
viewed and expert opinions were considered [14].
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recommendations and consensus
The levels of evidence were assigned according to the
classification system of the Oxford-Centre for Evidence
Based Medicine [15]. Grading of the strengths of recom-
mendations was done according to the German program
fordiseasemanagementguidelines:Thegradeofrecom-
mendation depends on the level of evidence. A strong
recommendation is based on a level of evidence class I,
a recommendation on a level of evidence class II and an
open recommendation on levels of evidence III, IV and V.
Negative recommendations are graded accordingly. An
up- or downgrading of recommendations is possible de-
pending on the consistency of the results of the studies,
the clinical relevance of the outcomes and effect sizes
of the studies, the benefit-harm ratio, ethical considera-
tions, patients’ preferences and the applicability of the
therapies[16].Wedowngradedrecommendationsifonly
one controlled study of the treatment option was avail-
able. We defined “consistent” if at least two controlled
studies with similar results were available or in case of
>twostudiesthemajority(≥75%)ofstudieshadthesame
results. Standardized procedures to reach a consensus
on recommendations were used. To reach consensus on
the final version of the guideline, five versions of the re-
commendations were developed and discussed in three
Delphirounds,oneonline-votingandtwomeetings,where
the Nominal Group Technique was applied. The strength
ofconsensuswasclassifiedasfollows:Strongconsensus:
consentof>95%,consensus:consentof75–95%,major-
ityconsent:consentof50–75%andnoconsent:consent
of <50% of the participants. A minority vote with a sub-
stantial rationale was possible.
The guideline was reviewed by the board of directors of
thesocietiesengagedinthedevelopmentoftheguideline.
The guideline was published online by the AWMF on april
25, 2008.
Clinical algorithms
Based on the recommendations a clinical algorithm for
a graded therapy of FMS was developed by one chair of
the steering committee and modified and consented by
the steering committee. A clinical algorithm structural
analysis was performed by Dr. Sitter, Institute of Theoret-
ical Surgery Marburg with the Software ALGO [17].
Results
Recommendations
The recommendations for the management of FMS in
children and adolescents are not reported here. An
overview on the recommendations is given in the Tables
1–4. In the following, we outline the reasons for up- and
downgrading. Furthermore we point out, if there is evid-
ence of the efficacy of treatment options after the end of
therapy.
General principles of therapy
Realistic aims of therapy should be developed with the
patient.Theprimaryaimsofthetherapyareimprovement
of functioning and adaptation to the symptoms. The
choiceoftreatmentoptionsshouldbebasedoninformed
decision-makingandrespectofthepatients’preferences.
Furthermore the local availability and cost of treatment
options as well as potential physical and mental comor-
biditiesofthepatientshouldbeconsidered.Thebenefits
and risks of any kind of therapy should be monitored
regularly by the patient and the physician. Any kind of
therapyshouldonlybecontinuedifthebenefitsoutweigh
the side effects. The recommendations are in favour of
active treatment options such as aerobic exercise and
psychological therapies because these modalities had
beenproventobesuperiortostandardmedicaltreatment
or treatment as usual. Moreover there is evidence that
some positive effects of active treatments persist after
the end of therapy. These active treatments can be
maintained after the end of a therapy programme by the
patient without medical assistance [18], [19], [20], [21].
Incontrastthereisonlyevidenceofasuperiorityofsome
pharmacological treatments over placebo with a maxim-
um length of study duration of six months. A continuous
pharmacological treatment can only be considered if an
ongoingbenefitcanbedetectedbyregularchecksbythe
patient and physician. A drug holiday after six months
pharmacological treatment is a further option [22].
Information on diagnosis
The upgrading into a very strong recommendation was
substantiatedbytwoarguments:Fromthepatients’point
ofviewthediagnosisofFMSoftenexplainsalonglasting
history of puzzling symptoms and frustrating odyssey
through the medical care system. From a physician’s
point of view there is an ethical obligation to inform a
patient on a diagnosis and its treatment options [18].
Education
Because patient education was part of most studies of
multicomponent treatment, patient education as an
integrated part of MT was strongly recommended [18].
Patient-centered communication
Anupgradingwasperformedbecauseofpatients’prefer-
ences [18].
Aerobic exercise
14/30 studies performed a follow-up. 13/14 studies re-
ported a sustained, but declining reduction of physical
symptoms [19].
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The studies included for analysis and a more detailed explanation for the changing of recommendations are provided in the
accompanying articles of the bibliography.
Table 2: Recommended treatments for the management of adult fibromyalgia syndrome
The studies included for analysis and a more detailed explanation for the changing of recommendations are provided in the
accompanying articles of the bibliography.
Psychotherapy
Cognitive behavioural therapy (CBT): Nine of 14 studies
performed a follow-up. Five studies reported positive ef-
fects in some outcomes at follow-up.
Relaxationtraining:Becauserelaxationtrainingwaspart
of some effective MT- or CBT-programs, an open recom-
mendation was given to use relaxation training as an in-
tegrated part of MT.
Psychodynamic therapy: Because systematic reviews
demonstrated the efficacy of psychodynamic therapy in
somatoform pain disorders, an open recommendation
was given for FMS-patients who also fulfil the criteria of
a somatoform pain disorder [20].
Physiotherapy and physical therapy
Massage,lymphdrainage,osteopathy:Anupgradingwas
done because of patients’ preferences within MT.
Whole body cold therapy: The recommendation was
downgraded because of the lacking validity of the out-
comes.
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The studies included for analysis and a more detailed explanation for the changing of recommendations are provided in the
accompanying articles of the bibliography.
Low energy laser and magnet field therapy: The recom-
mendations were downgraded, because the therapies
are not implemented into medical care in Germany [19].
Pharmacological therapy
Tricyclic antidepressants, serotonin-reuptake inhibitors,
noradrenaline-serotonine-reuptake inhibitors: We found
consistent positive results of amitriptyline, fluoxetine,
paroxetine and duloxetine. We found consistent negative
results of citalopram.
Monoaminooxidaseinhibitors:Therecommendationwas
downgraded because fatigue and sleeping difficulties in-
creased.
Cyclobenzaprine:Therecommendationwasdowngraded
because the drug is not licensed in most European
countries.
HT3-receptorantagonists:Therecommendationoftropis-
etron was downgraded because of the costs.
Tramadol, tramadol/aminoacetophen, ketamine, lido-
caine:Therecommendationsweredowngradedbecause
of the potential risks [22].
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The studies included for analysis and a more detailed explanation for the changing of recommendations are provided in the
accompanying articles of the bibliography.
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MT should include at least one psychological and one
exercise treatment. 13/14 studies performed follow-ups
of which 10 studies demonstrated positive effects of MT
[21].
Complementary and alternative therapies
Acupuncture: A systematic review concluded that acu-
puncture is not effective [23]. A minority vote considered
electroacupuncture as effective and that it should be
offered.Becauseofpatients’preferencesanopenrecom-
mendation was given within a MT-treatment.
Homeopathy,vegetarianandeliminationdiet,nutritional
supplements: The recommendations were downgraded
because of the lacking validity of the outcomes.
Melatonin, 5-Hydroxytryptophan, S’Adenosyl-Methionin:
The recommendations were downgraded because of the
lacking license in Germany.
Body-awareness, Feldenkrais, Tai-Chi or Qi Gong, music
therapy:Becauseofpatients’preferencesanopenrecom-
mendation was given within MT [24].
Invasive procedures
Tender point injections and electroconvulsive therapy:
Becauseofthepotentialharmstherecommendationwas
downgraded.
Transcranialmagnetstimulation:Becausethistreatment
option is not available in routine German medical care,
the recommendation was downgraded.
Blockades: Single epidural and regional sympathetic
blockadeswereusedinpathophysiologicalobservational
studies.Becauseofthepotentialsideeffectsofblockades
an open non-recommendation was given.
Surgical therapy: One author reported long-lasting pain
reliefaftermicrosurgicalreleaseofadhesionsatacupunc-
ture points in a case-series. There are potential harms of
thesurgery.Thereforeastrongnon-recommendationwas
given [19].
A stepwise management
AstepwisemanagementapproachisoutlinedinFigure1.
Thestepwiseapproachisbasedonthelevelsofevidence
and recommendation and costs. The first line therapies
hadthehighestlevelsofevidenceandrecommendation.
Multicomponent therapy recommended as second line
therapy is more costly than the first line therapies. The
timeframesprovidedfordecisionmakingcanbemodified
depending on the individual situation [18].
Discussion
13scientificsocietiesandtwopatientself-helporganisa-
tions developed a guideline on the management of FMS
based on evidence and formal consensus. They met the
following obstacles in giving evidence-based recommen-
dations:
• The symptoms and disabilities persist in most adult
FMS-patients over time. There is strong evidence for
the limited efficacy of some (non-)pharmacological
therapies. Most studies reviewed lasted only 4–12
weeks. Follow-ups are only available for aerobic exer-
cise, CBT and MT revealing declining positive effects.
The question which therapies should be offered over
which period, cannot be answered by the studies
available.
• All studies included mainly middle-aged Caucasian
women and excluded patients with severe physical
and mental disorders. The question how children and
adolescents,males,non-Caucasiansandpatientswith
severe comorbidities should be managed, cannot be
answered by the studies reviewed.
Considering the controversies between somatic and
psychosocialapproachesinFMS-therapy,theconsensus
reachedintheguidelineisremarkable.Somerecommen-
dations of the guideline are influenced by a national
perspective such as down-grading of recommendations
becauseoflackinglicenseorlackofimplementationinto
medical care in Germany and specific opportunities of
the German health system such as rehabilitation medi-
cine. Nevertheless the guideline group hopes that the
recommendations will be useful for patients and health
care providers in other countries.
The following steps to distribute the recommendations
of the guidelines had been done. Short versions of the
guidelinehadbeenpublishedinsomemembers'journals
of the societies involved [25]. Symposia on FMS and the
German guideline took place on scientific congresses of
the societies involved. The German Society of General
and Family Medicine is developing a pocket version of
the guideline, which will be evaluated. The guideline was
presented on patient-physician seminaries with regional
self-help organisations in several German cities (Köln,
München, Saarbrücken). The short version of the
guideline for patients was published in the members'
journals and is also available on the homepages of the
self-help organisations involved (http://www.rheuma-
liga.de; http://www.fibromyalgie-fms.de/). The guideline
will be completely revised in march 2011. Meanwhile
newstudiesonthemanagementofFMSarecontinuously
analysed. Appropriate to requirements earlier revisions
of the guideline are possible.
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